We have located links that may give you full text access.
Journal Article
Review
Management of Behçet's disease.
Current Opinion in Rheumatology 2018 May
PURPOSE OF REVIEW: Current treatment modalities in Behçet's disease will be summarized in light of new studies published within the last 2 years.
RECENT FINDINGS: There is an increasing interest in the treatment of refractory mucocutaneous symptoms of Behçet's disease, and results were quite promising with apremilast, anakinra, and ustekinumab. Data from large case series confirmed both the efficacy and safety of tumor necrosis factor-α inhibitors for the treatment of refractory major organ manifestations such as ocular, neurologic, vascular, and gastrointestinal involvement. In refractory ocular disease, long-term results also confirmed the efficacy and safety of interferon-α. Interleukin-1 inhibitors and tocilizumab seem to be alternative options in patients with refractory ocular involvement.
SUMMARY: Prospective and controlled studies for the management of major organ involvement in Behçet's disease are still limited. Data from primarily retrospective studies confirmed better outcomes of major organ involvement with tumor necrosis factor-α inhibitors and interferon-α. There were also acceptable results with interleukin-1 inhibitors for the management of refractory ocular disease, and with apremilast, anakinra, and ustekinumab for refractory mucocutaneous involvement.
RECENT FINDINGS: There is an increasing interest in the treatment of refractory mucocutaneous symptoms of Behçet's disease, and results were quite promising with apremilast, anakinra, and ustekinumab. Data from large case series confirmed both the efficacy and safety of tumor necrosis factor-α inhibitors for the treatment of refractory major organ manifestations such as ocular, neurologic, vascular, and gastrointestinal involvement. In refractory ocular disease, long-term results also confirmed the efficacy and safety of interferon-α. Interleukin-1 inhibitors and tocilizumab seem to be alternative options in patients with refractory ocular involvement.
SUMMARY: Prospective and controlled studies for the management of major organ involvement in Behçet's disease are still limited. Data from primarily retrospective studies confirmed better outcomes of major organ involvement with tumor necrosis factor-α inhibitors and interferon-α. There were also acceptable results with interleukin-1 inhibitors for the management of refractory ocular disease, and with apremilast, anakinra, and ustekinumab for refractory mucocutaneous involvement.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app